ReviewThe AAPS journal2006
Cannabinoid receptors and endocannabinoids: evidence for new players.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05567653 (Effects of 3-month Probiotic Mix Supplementation), which is not on this map. Cited by 112 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of 3-month Probiotic Mix Supplementation (L. Helveticus R-0052, B. Longum R-0175) on Gut Microbiota and Metabolome, Endocannabinoid and Immune Systems Activation, Along With Symptoms of Fatigue in Professional Dancers
Who cites it
112 citing papers in PubMed, 1 synthesis or guideline pooled it, 275 citations in OpenAlex.
- Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.Frontiers in immunology · 2021Pooled it
- Treatment of Migraine With Phytocannabinoids, the Involvement of Endocannabinoids in Migraine, and Potential Mechanisms of Action.Pain research & management · 2025Review
- Possible Combinatorial Utilization of Phytochemicals and Extracellular Vesicles for Wound Healing and Regeneration.International journal of molecular sciences · 2024Review
- Les données probantes et les recommandations sur le cannabis à des fins médicales chez les enfants.Paediatrics & child health · 2024Review
- Medical cannabis for children: Evidence and recommendations.Paediatrics & child health · 2024Review
- How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases.Therapeutic advances in chronic disease · 2023Review
- Pharmacokinetic modelling of orally administered cannabidiol and implications for medication control in horses.Frontiers in veterinary science · 2023Article
- Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.Biomedicines · 2022Review
- An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models.Molecules (Basel, Switzerland) · 2021Article
- Endocannabinoid signaling pathways: beyond CB1R and CB2R.Journal of cell communication and signaling · 2021Review
- Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review.IBRO neuroscience reports · 2021Article
- Cannabis and Migraine: It's Complicated.Current pain and headache reports · 2021Review
- Cannabinoid control of neurogenic inflammation.British journal of pharmacology · 2020Review
- The Cannabinoids Effect on Bone Formation and Bone Healing.Current osteoporosis reports · 2020Review
- THC Regulates Tearing via Cannabinoid CB1 Receptors.Investigative ophthalmology & visual science · 2020Article
- THC Exposure is Reflected in the Microstructure of the Cerebral Cortex and Amygdala of Young Adults.Cerebral cortex (New York, N.Y. : 1991) · 2020Article
- A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors.Molecules (Basel, Switzerland) · 2020Article
- Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures.Molecules (Basel, Switzerland) · 2020Article
- Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol.Frontiers in endocrinology · 2020Review
- Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.International journal of molecular sciences · 2019Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is now well established that the psychoactive effects of Cannabis sativa are primarily mediated through neuronal CB1 receptors, while its therapeutic immune properties are primarily mediated through CB2 receptors. Two endocannabinoids, arachidonoylethanolamide and 2-arachidonoylglycerol, have been identified, their action on CB1 and CB2 thoroughly characterized, and their production and inactivation elucidated. However, many significant exceptions to these rules exist. Here we review the evidence suggesting that cannabinoids can modulate synaptic transmission, the cardiovascular system, and the immune system through receptors distinct from CB1 and CB2, and that an additional "independent" endocannabinoid signaling system that involves palmitoylethanolamide may exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.